Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease modifying therapy for AD?

Todd E Golde1

  • 1Mayo Clinic College of Medicine, Department of Neuroscience, Mayo Clinic Jacksonville 4500 San Pablo Road., Jacksonville, Florida 32224, USA. tgolde@mayo.edu

Journal of Neurochemistry
|November 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein.

Acta neuropathologica communications·2026
Same author

Rigorous evaluation of pathological α-synucleinopathy transmissibility between animals in an experimental model.

Acta neuropathologica communications·2026
Same author

Successful strategies for supporting diverse representation in Alzheimer's disease research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Multi-scale integration of human brain vascular and CSF proteomes reveals biomarkers of cerebral amyloid angiopathy linked to Alzheimer's disease risk.

medRxiv : the preprint server for health sciences·2025
Same author

Sex-dependent effect of amyloidosis on functional network 'hub' topology is associated with downregulated neuronal gene signatures in the APP<i>swe</i>/PSEN1dE9 double transgenic mouse.

Journal of Alzheimer's disease : JAD·2025
Same author

Plasma proteomic associations with Alzheimer's disease endophenotypes.

Nature aging·2025

Developing new Alzheimer's disease (AD) therapies is crucial to prevent devastating costs. This review explores promising disease-modifying treatments targeting amyloid beta and tau, alongside existing symptomatic options.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Alzheimer's disease (AD) is the leading cause of dementia in industrialized nations, posing significant economic and societal burdens.
  • Current treatments, such as acetylcholinesterase inhibitors and memantine, offer symptomatic relief but are not disease-modifying.
  • Understanding AD pathogenesis has revealed novel therapeutic targets, including amyloid beta (Abeta) and tau accumulation.

Purpose of the Study:

  • To review the promise and challenges of developing disease-modifying therapies for Alzheimer's disease.
  • To highlight emerging therapeutic targets and their validation in preclinical and clinical studies.
  • To discuss the potential of therapies altering Abeta and tau accumulation.

Main Methods:

  • Review of current literature on Alzheimer's disease pathogenesis and therapeutic strategies.

Related Experiment Videos

  • Analysis of existing approved treatments and their limitations.
  • Examination of preclinical and clinical data for novel disease-modifying agents targeting Abeta and tau.

    • Main Results:

    • Existing AD drugs provide symptomatic benefits but do not alter disease progression.
    • Numerous targets for disease modification, primarily related to Abeta and tau, have been identified.
    • Preclinical validation exists for many novel targets, with some therapies progressing to clinical trials.

    Conclusions:

    • Significant promise exists for disease-modifying therapies targeting Abeta and tau in Alzheimer's disease.
    • Obstacles remain in translating preclinical findings into effective clinical treatments.
    • Further research and development are essential to overcome challenges and deliver impactful AD therapies.